Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

3.480 +0.230 (+7.08%)
Streaming Delayed Price Updated: 12:17 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.
From Lantern Pharma
Via Business Wire
News headline image
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
From Lantern Pharma Inc.
Via Business Wire
News headline image
7 AI Penny Stocks That Could Skyrocket in 2023 ↗
AI penny stocks represent great potential and high returns, given the fact this technology is only beginning to pervade society. 
Via InvestorPlace
News headline image
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
From Lantern Pharma Inc.
Via Business Wire
News headline image
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
From Lantern Pharma Inc.
Via Business Wire
BioMedNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) to Present at RHK Capital Disruptive Growth Conference
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
News headline image
Earnings Preview: Lantern Pharma ↗
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Lantern Pharma... 
Via Benzinga
News headline image
Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.